| Name | Title | Contact Details |
|---|
Based in Philadelphia, Aro Biotherapeutics is a biotechnology company pioneering the development of tissue-targeted genetic medicines with a platform based on a proprietary protein technology called Centyrins. The company is developing a wholly-owned pipeline of Centyrin-based therapeutic candidates and is working with industry partners to leverage Centyrins for tissue-specific targeting of therapeutics for a diverse set of diseases.
KBI BioPharma is a Durham, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Signum Biosciences Inc is a Monmouth Junction, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
At Outpost, we are committed to developing novel therapeutics for the treatment of gastrointestinal and urologic disorders. The company`s lead clinical-stage product candidate is in development for the treatment of overactive bladder (OAB) and irritable bowel syndrome (IBS). Located in Indianapolis and London, Outpost is a private company launched in 2016 with a $61 million Series A venture capital financing from Frazier Healthcare Partners, Adams Street Partners, Novo Holdings A/S, Vivo Capital, and Takeda Ventures.
MANA was founded in November 2018, based on the research and human proof-of-concept clinical trials conducted by Dr. Catherine Bollard and her team at Children`s National Hospital (CNH) in Washington, D.C., along with colleagues at Johns Hopkins Medical Center.